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ABSTRACT
Assessing Functional Vasodilation in the Gracilis Collateral Arteriole
Megan Chu
Peripheral arterial occlusive disease (PAOD) involves arterial occlusion due to the formation of
atherosclerotic plaques. It is suggested that intermittent claudication, the most frequent clinical
presentation of PAOD, is caused by impaired vasodilation. Current treatments for PAOD are not
directed at improving vascular reactivity and are often insufficient. Stimulating arteriogenesis in
collateral arterioles has therapeutic potential for PAOD, but because arterioles are the primary
site of blood flow resistance, it is important that these treatments do not impair collateral
vasodilation. Before this can be evaluated, the effects of arteriogenesis on collateral function
must be studied in untreated collaterals. There is impaired functional vasodilation at the
collateral stem following collateral enlargement in the mouse hindlimb ischemia model. In order
to determine if a similar impairment occurs at the collateral midzone, visualization of the gracilis
collateral arteriole must be improved. In this study, we tested the hypotheses that FITC-dextran
injected into the intravascular space would allow visualization of the gracilis collateral arteriole
using epifluorescence, and that a trans-illumination device placed deep to the gracilis muscle
would allow visualization of the arteriole by backlighting the midzone. Both of these methods
allowed for clear visualization of the gracilis vasculature. Additionally, the placement of the
trans-illumination device did not affect vasodilation in the upstream feed artery, suggesting that
collateral reactivity would also remain unaltered by the device. In future studies, both of these
visualization techniques will be employed to assess functional vasodilation in the midzone of the
gracilis collateral arteriole in both unoperated animals and those with ligation-induced ischemia.
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INTRODUCTION
Peripheral Arterial Occlusive Disease
Peripheral arterial occlusive disease (PAOD) affects eight to ten million Americans, causing
500,000 hospitalizations and 100,000 angiograms in the United States annually [1]. This
condition is associated with increased risk of myocardial infarction, stroke, and vascular death.
PAOD is most commonly caused by atherosclerotic plaques that build up in the arteries and
restrict blood flow to the downstream tissue (Figure 1).

Figure 1. Peripheral arterial occlusive disease (PAOD). PAOD is characterized by atherosclerotic plaques that
form inside arteries and decrease blood flow to the tissue [2].

Ankle-brachial index (ABI), which is the ratio of the highest systolic blood pressure in the lower
limb to that of the arm, is commonly used for the diagnosis of PAOD (ABI<0.9) [3]. The most
severe form of PAOD is critical limb ischemia (CLI, ABI<0.4), which is present in 12 percent of
the adult population and is characterized by ischemic pain at rest [1]. CLI occurs due to
inadequate blood flow to the lower limbs and thrombotic complications, and often results in limb
loss [3]. Before the disease progresses to this point, the most frequent clinical presentation of
PAOD is intermittent claudication (ABI=0.4-0.9), or leg pain that occurs with exertion but not at

rest [4]. One proposed cause for intermittent claudication is impaired vascular reactivity. When
L-arginine was used to restore NO synthesis, and consequently, endothelium-dependent
vasodilation, claudication symptoms in PAOD patients improved [5]. Additionally, supervised
exercise conditioning in patients with PAOD led to an increase in treadmill exercise performance
as well as reduced claudication pain during exercise [6]. That exercise training improves
claudication symptoms indicates impaired vasodilation as a cause of intermittent claudication.
Current treatments for PAOD include pharmacological therapy, endovascular intervention by
angioplasty or stenting, and bypass grafting. Anti-platelet and anti-inflammatory medications
such as pentoxifylline are considered minimally effective, producing only small improvements in
walking distance of patients, while vasodilators such as cilostazol improve walking distance but
cannot be used in patients with heart failure [6]. Peripheral bypass therapy improves treadmill
exercise performance and functional status in patients with claudication [6]. However, bypass
therapy for claudication has high short-term costs in terms of morbidity, mortality, and health
care [6]. Many patients who undergo bypass grafting end up with bypass occlusion and CLI,
resulting in a greater risk of limb loss and the need for additional procedures. The goal of both
surgical and pharmocological therapies is to counteract the negative effects of atherosclerosis.
However, none of these treatments aim to improve vascular reactivity.
Arteriogenesis
Although they do lead to improvement in some patients, the current approaches to treating
PAOD are often insufficient, and developing therapies based on processes that occur naturally in
the body are promising. Pre-existing collateral networks can function as natural bypasses around
an occlusion to restore blood flow. A blockage in an artery leads to a decrease in pressure
downstream of the occlusion, which increases the pressure gradient across the collateral. This
2

increase in shear stress causes these arterioles to increase in diameter through the process of
arteriogenesis [7]. Following endothelial activation, the presentation of adhesion molecules such
as ICAM is increased and monocyte chemoattractant protein-1 (MCP-1) is secreted, causing
monocytes in the circulation to extravasate and differentiate into macrophages. These cells
secrete a number of arteriogenic factors, including tumor necrosis factor (TNF-α) for smooth
muscle cell proliferation, vascular endothelial growth factor (VEGF) for endothelial cell
proliferation, and matrix metalloproteinases (MMPs) for basement membrane and matrix
degradation. Smooth muscle cells and fibroblasts are responsible for the synthesis of a new
matrix [8].
Arteriogenesis is important because of its therapeutic potential for the treatment of PAOD, but
the development of therapies to stimulate arteriogenesis warrants investigation into the impact of
these treatments on collateral vasodilation, as the collateral circulation is the primary site of
blood flow resistance in the ischemic limb and proper control of blood flow is necessary to meet
the metabolic demands of the tissue. However, this can only occur after collateral function is
studied in untreated collaterals during and after arteriogenesis.. Chronic ischemia causes
impaired functional vasodilation in the collateral stem due to collateral enlargement through
mechanoadaptation [9,10]. It is important to investigate the effects of arteriogenesis on
vasodilation in the collateral midzone to determine if similar impairment is observed.
A common animal model for PAOD is the mouse hindlimb model, where a collateral network is
present in the gracilis muscle (Figure 2).
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Figure 2. Gracilis Collateral Circuit. The three sections of the gracilis collateral circuit in the mouse hindlimb.

However, the gracilis tissue is relatively thick as well as optically dense, and the collateral
arteriole is located deep within the muscle. This leads to poor visualization of the arteriole,
making it difficult to gauge the vasodilation of the vessel in response to a stimulus.
Vasculature Visualization Techniques
There are different techniques that are currently employed to visualize blood vessels in vivo.
First, laser speckle imaging can be used to create detailed vasculature maps based on optical
scattering during blood flow [11]. A low-power laser generates time-integrated speckle patterns,
which are converted to flow images [12]. For instance, laser speckle imaging provided high
spatial resolution maps of relative blood flow in a rodent skin fold model [12]. This technique is
well-suited for this model because the large vessel diameters (50-200 µm) allow for flow
monitoring over a wide field of view [12]. Laser speckle imaging is particularly useful in tissues
with superficial vessels [12], but optical scattering diminishes the ability to visualize subsurface
microvasculature [13], which could be the case for the arteriole in the gracilis muscle.
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Another technique that allows for the visualization of vasculature in vivo is sidestream dark field
(SDF) imaging. The probe used in this imaging modality consists of a central light guide
surrounded by light emitting diodes (LEDs), which illuminate the microcirculation by scattering
[14]. The emission wavelength of the LEDs is 530 nm, so that the scattered green light is
absorbed by hemoglobin in the red blood cells of superficial vessels at a tissue depth of up to 3
mm [15]. The physiological cross-sectional area of the gracilis anterior is 1.1 ± 0.5 cm2 [16].
Assuming a circular cross-sectional area, the muscle radius is about 3.3 mm and the muscle
diameter is about 6.7 mm. Therefore, SDF imaging may not allow for deep enough penetration to
effectively visualize the gracilis collateral arteriole. Additionally, microcirculatory alterations
may be induced by the pressure from the application of the probe onto the tissue surface [14].
Other attempts to visualize blood vessels in vivo utilize fluorescein isothiocyanate-conjugated
dextran (FITC-dextran), which is a fluorescent dye that emits green light when excited. To assess
vascular permeability in mice, varying molecular weights of FITC-dextran were injected into the
bloodstream [17]. At low molecular weights, fluorescence intensity decreased in the blood vessel
area and increased in the interstitial space; however, at high molecular weights, the dextran
remained in circulation [17]. Based on this disparity, high-molecular weight FITC-dextran was
delivered by retro-orbital injection to improve visualization of retinal blood vessels, and
successfully allowed for the quantification of neovascularization area [18]. Injection of FITCdextran at a high molecular weight may also improve visualization of the gracilis collateral
arteriole enough to measure vasodilation.
Another technique for blood vessel visualization involves the use of trans-illumination. In a
study exploring a novel method for in vivo trans-illumination, the mouse cremaster muscle was
surgically isolated from the surrounding tissue in vivo so that it could be placed on a transparent
5

pedestal of silastic rubber during continuous superfusion of a physiological salt solution and
trans-illuminated with an intravital microscope [19,20]. While this preparation made use of the
trans-illumination capabilities of a microscope outside the body of the anesthetized animal, it is
also possible to create a device specifically for trans-illumination in microcirculatory regions that
are more difficult to access. In an in vivo flow cytometry study, the mouse ear was transilluminated with a device containing a green LED to identify the proper blood vessel location for
the flow cytometry measurements [21]. In the mouse ear, the blood vessels are about 70-100 µm
from the surface, and the appropriate vessel size range for trans-illumination is roughly 20-50
µm [21]. Because the gracilis collateral arteriole ranges from about 15-25 µm [22], transillumination may be a promising method for visualizing vasodilation of this arteriole in response
to a stimulus.
Objectives
The goal of this study was to assess approaches to visualize functional vasodilation in the gracilis
collateral arteriole. To achieve this goal, we tested two hypotheses:
1.

FITC-dextran injected into the intravascular space will allow visualization of the gracilis

collateral arteriole using epifluorescence.
2.

A trans-illumination device placed deep to the gracilis muscle will backlight the midzone

and allow visualization of the collateral arteriole.
Supporting either of these methods in an unoperated animal model will allow the completion of
future studies to study vasodilation during and after arteriogenesis following ligation-induced
ischemia.
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METHODS
Animal Preparation
All experimental protocols were approved by the California Polytechnic State University
Institutional Animal Care and Use Committee (IACUC). Male and female albino ICR mice were
housed in a temperature-controlled environment in the University Vivarium and were provided
with food, water, and enrichment (bedding, mouse house, and tunnel tube).
Mice were anesthetized in an induction chamber using 5% isofluorane in oxygen at 0.8-1.0
1·min-1. Animals were weighed and moved to a preparatory bench, where the isofluorane was
decreased to 2-3% and the flow rate was adjusted as necessary. Hair was removed from the
hindlimb region using depilatory cream, and skin was disinfected using chlorhexidine diacetate.
Mice were then placed on a microscope stage with a heating pad that maintained body
temperature at 35°C, as measured by a rectal thermistor probe.
An incision was made in the medial aspect of the hindlimb, and blunt dissection was used to
expose the gracilis muscle and remove overlying fascia and connective tissue. The tissue was
irrigated periodically with phosphate-buffered saline (PBS) to prevent desiccation.
Functional Vasodilation
Two tungsten microelectrodes were placed near the motor-end plate of the gracilis muscle,
halfway between the profunda and the saphenous arteries. A data acquisition unit
(ADInstruments PowerLab) and digital chart recording software (LabChart) were used to
stimulate muscle contraction with 1 mA square waves with a duration of 200 µs and a frequency
of 1 Hz, to optimize electrode placement for maximal localized gracilis contraction. The exposed
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area was then irrigated with PBS and covered with plastic wrap, and the preparation equilibrated
for 30 minutes.
After the equilibration period, images of the profunda femoris artery were captured using an
intravital microscope (Olympus BXFM) and digital imaging software (QCapture Pro). Then, the
muscle was stimulated for 90 seconds with 1 mA square waves with a duration of 200 µs and a
frequency of 8 Hz. Starting immediately after stimulation, images of the profunda were captured
every minute until it returned to its resting diameter.
Effects of Trans-Illumination Device Insertion on Functional Vasodilation
Using blunt dissection, a pocket was created deep to the anterior and posterior gracilis muscles.
After electrode placement and equilibration, described above, functional vasodilation was
assessed at the profunda femoris. Then, the electrodes were removed and the
polydimethylsiloxane-coated LED trans-illumination device was placed in the pocket deep to the
gracilis muscles (Figure 3A-B), followed by a second electrode placement, equilibration period,
and vasodilation measurement.

Figure 3. Trans-Illumination Device Placement. The LED trans-illumination device was inserted under the
anterior and posterior gracilis muscles (A). When turned on, the light was used to backlight the muscle for better
visualization of the collateral arteriole in the gracilis anterior (B). Electrodes were placed on the gracilis muscle in
the location shown for functional vasodilation measurement (C).
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Collateral Visualization with Trans-Illumination
To measure collateral vasodilation, the LED was adjusted to the desired brightness and
positioned in the pocket deep to the gracilis muscles for an optimal view of the collateral
arteriole midzone. After electrode placement and equilibration, described above, resting images
of the midzone were captured. Then, functional vasodilation was assessed at the midzone.
Images were captured every minute for ten minutes immediately following stimulation.
Collateral Visualization with FITC-Dextran
Fluorescein isothiocyanate-dextran (FITC-dextran, 250000 MW dextran, 0.1 ml) was injected
intravascularly via jugular venipuncture. These experiments were performed with minimal
lighting to avoid photo-bleaching the FITC-dextran. The collateral vessels in the gracilis anterior
were visualized via epifluorescent illumination with an intravital microscope. Functional
vasodilation was measured at the midzone of the collateral, as described above. After each
experiment, mice were euthanized by cervical dislocation.
Data Analysis
ImageJ software was used to measure vessel diameter. Percent changes in diameter were
calculated as the difference between the dilated and resting diameters divided by the resting
diameter and multiplied by 100%. Paired t-tests were used to compare the resting and dilated
diameters of the profunda femoris artery under normal conditions, after undermining the gracilis,
and after inserting the trans-illumination device. ANOVA was used to detect differences in
profunda diameter between the three sets of conditions, both at rest and after electrical
stimulation, and also to detect differences in percent change in diameter between the three sets of
conditions. Data are presented as mean ± SE.
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RESULTS
Improving the visualization of the gracilis collateral arteriole is necessary to assess functional
vasodilation. In this experiment, we tested the hypotheses that either placing a trans-illumination
device deep to the gracilis muscle or injecting FITC-dextran into the intravascular space would
allow visualization of the collateral arteriole.
Functional vasodilation was observed in the profunda femoris artery (Figure 4A) following
electrical stimulation of the gracilis muscle under normal conditions, after undermining the
gracilis, and after inserting the LED trans-illumination device deep to the muscle (Figure 4B-C).

A

*

*

* B

C

Figure 4. Trans-Illumination Device Insertion Does Not Affect Vasodilation. Vasodilation in the profunda was
measured in the location shown (A) following stimulation normally, after undermining the gracilis, and after
inserting the LED device. B) Vessel diameter before and after stimulation. C) Percent change in vessel diameter.
Vessel diameter increased with electrical stimulation, but there was no difference in percent change between the
three sets of conditions. *p < 0.05, n=4

10

The dilated diameter of the profunda was larger than the resting diameter in each category.
Under normal conditions, the resting diameter was 66 ± 3 µm and the diameter after stimulation
was 97 ± 5 µm. After undermining the gracilis, the diameter was 71 ± 2 µm resting and 101 ± 3
µm after stimulation. With the trans-illumination device inserted, the diameter was 70 ± 3 µm
resting and 99 ± 3 µm after stimulation. Neither the resting nor the dilated diameters measured
after undermining the gracilis or inserting the trans-illumination device were different from the
respective values under normal conditions. The percent change in diameter with stimulation was
48 ± 7 percent under normal conditions, 42 ± 5 percent with the gracilis undermined, and 41 ± 5
percent with the trans-illumination device inserted.
Because inserting the trans-illumination device had no adverse effects on vasodilation in the
profunda, it was then used to visualize the functional vasodilation of the collateral midzone. A
montage of representative images of the gracilis illuminated by the LED displays the entire
collateral arteriole (Figure 5).

Figure 5. Gracilis Collateral Arteriole with Trans-Illumination. Images of the gracilis collateral arteriole were
captured by placing a trans-illumination device deep to the muscle for improved visualization (n=3).
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Trans-illuminating the gracilis muscle allowed for distinct visualization of the blood vessels.
However, the LED was so bright that it obscured the view of any vasculature located directly
above it, making it necessary to move the probe around to visualize different vessels.
Additionally, it was difficult to distinguish the arteriole from the venule in the gracilis anterior.
Although trans-illumination allowed for clear visualization, no midzone dilation was observed
following stimulation in any of the replicates.
An alternative approach to enhance contrast in the gracilis muscle involved the intravascular
injection of FITC-dextran to better view the collateral arteriole. After injection of the fluorescent
dye, the gracilis vasculature appeared bright green (Figure 6).

Figure 6. Gracilis Collateral Arteriole after FITC-Dextran Injection. The stem (A), midzone (B), and re-entry
(C) of the gracilis collateral circuit were imaged with fluorescence after injection of FITC-dextran (n=4).

However, despite the clarity of the gracilis muscle with epifluorescent illumination of FITCdextran injection, it was still difficult to determine which vessel was the collateral arteriole.
There was no midzone dilation observed in any of the visible vessels after electrical stimulation.
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DISCUSSION
Intermittent claudication, the most frequent clinical presentation of PAOD, may be caused by
impaired vasodilation. Current treatments for PAOD are not directed at improving vascular
reactivity, and are often insufficient. Stimulating arteriogenesis in collateral arterioles has
therapeutic potential for PAOD, but it is important that these treatments do not impair collateral
vasodilation. Before this can be evaluated, the effects of arteriogenesis on collateral function
must be studied in untreated collaterals. There is impaired functional vasodilation at the
collateral stem following collateral enlargement in the mouse hindlimb ischemia model. To
determine if a similar impairment occurs at the collateral midzone, visualization of the gracilis
collateral arteriole must be improved. In this study, we tested the hypotheses that FITC-dextran
injected into the intravascular space would allow visualization of the gracilis collateral arteriole
using epifluorescence, and that a trans-illumination device placed deep to the gracilis muscle
would allow visualization of the arteriole by backlighting the midzone.
The first method that we explored involved a trans-illuminating LED device that was placed
deep to the gracilis muscles. Using this device to backlight the collateral arteriole improved
contrast and allowed for visualization of the blood vessels in the area, supporting our hypothesis.
However, the device required constant manipulation to clearly view different regions of the
gracilis, mostly due to the brightness of the LED, which obscured any vasculature located
directly above it. Future versions of the trans-illumination device could include a dimmer switch
to reduce the brightness of the light. Additionally, instead of placing the device deep to the
gracilis muscles, the hair could be removed from the posterior side of the hindlimb so that the
device could shine through the entire limb, which would also reduce its brightness.
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In order to use this technique to visualize collateral vasodilation in response to a stimulus, it was
necessary to confirm that the device itself did not affect vasodilation. Neither undermining the
gracilis nor inserting the trans-illumination device had an effect on functional vasodilation in the
profunda. Based on this observation, it can be assumed that functional vasodilation in the
collateral midzone is similarly unaffected by these methods. Future studies could be conducted to
determine how large of an LED probe it would take to alter reactivity in the profunda.
In subsequent experiments performed to observe functional vasodilation in the midzone of the
collateral arteriole, there was no change in diameter of the arteriole following electrical
stimulation. The lack of vasodilation could be explained by visualization of the venule instead of
the arteriole. However, there was also no dilation of the profunda femoris artery in the same
experiments, suggesting that another factor was affecting vasodilation. Although the only reagent
used was PBS, it is possible that contamination occurred. The acute inflammatory response
triggered by microbial infection involves vasodilation to increase the delivery of plasma and
leukocytes to the site of infection [23]. If the vessels in the gracilis collateral circuit were already
dilated, they might not increase in diameter further in response to an electrical stimulus. To avoid
any contamination in the future, sterile saline could be applied to the tissue in place of PBS to
prevent desiccation.
After exploring trans-illumination to improve visualization, we used epifluorescence following
FITC-dextran injection to visualize the gracilis collateral arteriole. FITC-dextran successfully
caused the vasculature in the gracilis muscle to fluoresce, supporting our hypothesis. However,
in addition to the blood vessels, the surrounding tissue also turned green, though not as brightly.
This is likely due to tissue autofluorescence, which can appear green from a variety of
components. For instance, lipofuscins, elastin, and collagen all have excitation spectra that
14

include blue and emission spectra that include green, similar to FITC-dextran [24]. Because of
this, it may be beneficial to experiment with the use of a fluorescent dye other than FITCdextran. A red dye such as tetramethylrhodamine isothiocyanate-conjugated dextran (TRITCdextran, Sigma-Aldrich) might provide a clearer image of the hindlimb circulation with better
visualization of the collateral arteriole.
Although visualization with FITC-dextran appeared promising aside from the possible
autofluorescence, there were again no diameter changes in the visible gracilis vasculature after
electrical stimulation. As with trans-illumination, we initially assumed that the major visible
blood vessel was the venule that runs throughout the length of the gracilis. Arterioles are much
more reactive than venules due to a thicker tunica media, so it was expected that vessels that
changed in diameter were arterioles, while those that did not were venules. Once again, however,
the profunda remained similarly unaffected by stimulation, suggesting that the lack of
vasodilation was caused by another factor, potentially the contamination of a reagent such as
PBS. Therefore, the visible blood vessel in the gracilis muscle could have been either the
arteriole or the venule.
In future studies, it may be necessary to evaluate other indicators, instead of relying on a
vasodilation response to distinguish between vessel types. For example, venule diameter is
generally larger than the corresponding arteriole diameter. Then, when using a fluorescent dye
such as FITC-dextran, high magnification can allow for the visualization of blood flow through
the vessels. The direction of blood flow is opposite in the two vessel types, and the velocity of
blood flow is generally greater in arterioles than in venules [25]. These small visual differences
can be utilized in vivo to differentiate between the gracilis blood vessels.
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In conclusion, visualization must be improved to measure functional vasodilation in the midzone
of the gracilis collateral arteriole. Placing a trans-illumination device deep to the gracilis muscle
does not affect vasodilation in the upstream feed artery, suggesting that collateral vasodilation
remains unaltered as well. Trans-illumination also improves the contrast between the blood
vessels in the gracilis and the surrounding tissue for clear visualization. Injecting FITC-dextran
causes the blood vessels in the gracilis to fluoresce, also allowing for clear visualization of the
vasculature. As a next step, either of these methods can be used to observe vasodilation in the
profunda femoris artery and the gracilis collateral midzone in unoperated animals. Then, the
effects of ligation-induced ischemia and arteriogenesis on vasodilation in the midzone of the
collateral arteriole will be assessed using similar visualization techniques.
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APPENDIX A: Functional Vasodilation Protocol
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APPENDIX B: Experimental Set-Up
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APPENDIX C: Sample Raw Images
Profunda femoris artery, normal conditions – resting (left) and dilated (right)

Profunda femoris artery, gracilis undermined – resting (left) and dilated (right)

Profunda femoris artery, LED probe inserted – resting (left) and dilated (right)
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Gracilis collateral midzone with FITC-dextran

Gracilis collateral midzone with trans-illumination device
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APPENDIX D: Raw Data
Replicate
1
2
3
4
5
6
7
8

Resting (µm)
58.23523468
72.34582461
70.58615104
66.60198447
74.10549818
67.06680391
67.49842195
48.97204741

Normal
Dilated (µm)
111.1582473
102.326678
77.62484531
100.1353864
109.3985737
98.8073309
103.2231155
72.34582461

% Change
90.87799
41.44103
9.971778
50.34895
47.62545
47.32673
52.92671
47.72881

Gracilis undermined
Resting (µm) Dilated (µm) % Change
67.06680391 108.5021362 61.78218
78.52128279 97.94409481 24.73573
82.04062993 108.5021362 32.25415
75.00193565 109.8301917 46.43648
64.41069286 108.5021362 68.45361
69.68971356 97.94409481 40.54312
73.67388013 95.71960181 29.92339
57.80361663 81.60901188 41.18323
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Resting (µm)
60.89134572
79.41772027
86.45641454
62.65101929
71.44938713
69.68971356
74.10549818
58.23523468

LED probe
Dilated (µm)
102.326678
103.2231155
106.7424627
94.39154629
101.4634419
95.28798377
107.2072821
82.04062993

% Change
68.04798
29.97492
23.4639
50.66243
42.00743
36.73178
44.66846
40.87799

APPENDIX E: Statistical Analysis
Paired T-Tests Comparing Resting and Dilated Diameters

Anderson Darling Normality Test
Normal
Gracilis undermined
LED probe
Resting (µm) Dilated (µm) % Change Resting (µm) Dilated (µm) % Change Resting (µm) Dilated (µm) % Change
AndersonDarling p-value

0.125

0.057

0.022

0.974

Sample Normal Probability Plots
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0.063

0.502

0.852

0.192

0.674

Bartlett’s Test for Equal Variance and ANOVA [Resting Diameter]

Bartlett’s Test for Equal Variance and ANOVA [Dilated Diameter]

Levene’s Test for Equal Variance and Kruskal-Wallis Test [Percent Change]*

*When one or more data sets is not normal, Levene’s Test can be used to determine equal variances and the
Kruskal-Wallis Test can be used for comparison of medians.
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